Diagnostic accuracy of anti-3-[18F]-FACBC PET/MRI in gliomas.

Purpose: The primary aim was to evaluate whether anti-3-[18F]FACBC PET combined with conventional MRI correlated better with histomolecular diagnosis (reference standard) than MRI alone in glioma diagnostics. The ability of anti-3-[18F]FACBC to differentiate between molecular and histopathological e...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 51; no. 2; pp. 496 - 510
Autores principales: Karlberg, Anna, Pedersen, Lars Kjelsberg, Vindstad, Benedikte Emilie, Skjulsvik, Anne Jarstein, Johansen, Håkon, Solheim, Ole, Skogen, Karoline, Kvistad, Kjell Arne, Bogsrud, Trond Velde, Myrmel, Kristin Smistad, Giskeødegård, Guro F., Ingebrigtsen, Tor, Berntsen, Erik Magnus, Eikenes, Live
Formato: Journal Article
Publicado: Springer Nature Jan2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=174658098&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 174658098
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: Jan2024
      vid: 51
      iid: 2
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        174658098
        172388811
        10.1007/s00259-023-06437-4
        174658098
      ppf: 496
      ppct: 14
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Diagnostic accuracy of anti-3-[18F]-FACBC PET/MRI in gliomas.
      aug:
        au:
          Karlberg, Anna
          Pedersen, Lars Kjelsberg
          Vindstad, Benedikte Emilie
          Skjulsvik, Anne Jarstein
          Johansen, Håkon
          Solheim, Ole
          Skogen, Karoline
          Kvistad, Kjell Arne
          Bogsrud, Trond Velde
          Myrmel, Kristin Smistad
          Giskeødegård, Guro F.
          Ingebrigtsen, Tor
          Berntsen, Erik Magnus
          Eikenes, Live
        affil: Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Prinsesse Kristinas gate 3, N-7030, Trondheim, Norway
      sug:
      ab: Purpose: The primary aim was to evaluate whether anti-3-[18F]FACBC PET combined with conventional MRI correlated better with histomolecular diagnosis (reference standard) than MRI alone in glioma diagnostics. The ability of anti-3-[18F]FACBC to differentiate between molecular and histopathological entities in gliomas was also evaluated. Methods: In this prospective study, patients with suspected primary or recurrent gliomas were recruited from two sites in Norway and examined with PET/MRI prior to surgery. Anti-3-[18F]FACBC uptake (TBRpeak) was compared to histomolecular features in 36 patients. PET results were then added to clinical MRI readings (performed by two neuroradiologists, blinded for histomolecular results and PET data) to assess the predicted tumor characteristics with and without PET. Results: Histomolecular analyses revealed two CNS WHO grade 1, nine grade 2, eight grade 3, and 17 grade 4 gliomas. All tumors were visible on MRI FLAIR. The sensitivity of contrast-enhanced MRI and anti-3-[18F]FACBC PET was 61% (95%CI [45, 77]) and 72% (95%CI [58, 87]), respectively, in the detection of gliomas. Median TBRpeak was 7.1 (range: 1.4–19.2) for PET positive tumors. All CNS WHO grade 1 pilocytic astrocytomas/gangliogliomas, grade 3 oligodendrogliomas, and grade 4 glioblastomas/astrocytomas were PET positive, while 25% of grade 2–3 astrocytomas and 56% of grade 2–3 oligodendrogliomas were PET positive. Generally, TBRpeak increased with malignancy grade for diffuse gliomas. A significant difference in PET uptake between CNS WHO grade 2 and 4 gliomas (p < 0.001) and between grade 3 and 4 gliomas (p = 0.002) was observed. Diffuse IDH wildtype gliomas had significantly higher TBRpeak compared to IDH1/2 mutated gliomas (p < 0.001). Adding anti-3-[18F]FACBC PET to MRI improved the accuracy of predicted glioma grades, types, and IDH status, and yielded 13.9 and 16.7 percentage point improvement in the overall diagnoses for both readers, respectively. Conclusion: Anti-3-[18F]FACBC PET demonstrated high uptake in the majority of gliomas, especially in IDH wildtype gliomas, and improved the accuracy of preoperatively predicted glioma diagnoses. Clinical trial registration : ClinicalTrials.gov ID: NCT04111588, URL: https://clinicaltrials.gov/study/NCT04111588
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N